protein kinase C deltaGenealiases: ALPS3 · CVID9 · MAY1 · PKCD · nPKC-delta
Q-omics provides the consensus-scored PRKCD profile across patient tissues and cancer cell-line models. PRKCD expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PRKCD is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, PRKCD protein abundance shows 21,581 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, KICH, and GBM as cancer lineages where PRKCD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRKCD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRKCD survival associations across molecular data types. PRKCD RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRKCD RNA expression–survival associations across cancer types. High PRKCD expression shows unfavorable associations in LIHC, KIRP, LGG and MESO, but favorable associations in UVM and LUAD. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PRKCD RNA expression.
This table summarizes PRKCD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in KICH for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for PRKCD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRKCD shows lower tumor expression in LUSC, KIRC, LUAD and KIRP and higher tumor expression in KICH and LIHC. The KICH box plot shows higher PRKCD RNA expression in tumor versus normal tissue (log2 FC = +2.065, t-test p < 0.001).
This table shows molecular features associated with PRKCD in patient tissues and cancer cell lines. In patient samples, PRKCD shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRKCD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
